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Abstract
Metastatic melanoma is the most aggressive skin cancer. Recently, phenotypically distinct subpopulations of tumor cells
were identified. Among them, ABCB5-expressing cells were proposed to display an enhanced tumorigenicity with stem cell-
like properties. In addition, ABCB5
+ cells are thought to participate to chemoresistance through a potential efflux function of
ABCB5. Nevertheless, the fate of these cells upon drugs that are used in melanoma chemotherapy remains to be clarified.
Here we explored the effect of anti-melanoma treatments on the ABCB5-expressing cells. Using a melanoma xenograft
model (WM266-4), we observed in vivo that ABCB5-expressing cells are enriched after a temozolomide treatment that
induces a significant tumor regression. These results were further confirmed in a preliminary study conducted on clinical
samples from patients that received dacarbazine. In vitro, we showed that ABCB5-expressing cells selectively survive when
exposed to dacarbazine, the reference treatment of metastatic melanoma, but also to vemurafenib, a new inhibitor of the
mutated kinase V600E BRAF and other various chemotherapeutic drugs. Our results show that anti-melanoma
chemotherapy might participate to the chemoresistance acquisition by selecting tumor cell subpopulations expressing
ABCB5. This is of particular importance in understanding the relapses observed after anti-melanoma treatments and
reinforces the interest of ABCB5 and ABCB5-expressing cells as potential therapeutic targets in melanoma.
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Introduction
Melanoma is one of the most aggressive form of skin cancer and
its incidence is increasing worldwide, especially where fair-skinned
people receive excessive sun exposure [1–3]. Primary tumors
without any evidence of metastases are mostly treated by surgery.
However, metastatic melanoma is highly resistant to conventional
radio and chemotherapies and remains a disease of poor
prognosis, with median survival times comprised between 7 and
9 months. A number of chemotherapeutic agents (such as
dacarbazine, temozolomide or fotemustine) alone or in combina-
tion have a limited activity with relatively low response rates
(,25% for any single agent) [4,5] and so far only a small impact
on overall survival. Even if some promising targeted therapies are
currently developed with new BRAF kinase inhibitors such as
vemurafenib [6], melanomas invariably become resistant to these
agents [7]. Thus, chemoresistance remains a serious concern for
melanoma therapy.
Besides the mechanisms of resistance to chemotherapy that are
shared by various cancers, melanomas display specific features.
Melanoma cells are equipped with melanogenesis-related vesicles,
the melanosomes, that have been shown to be involved in drug
trapping and export [8]. Secondly, these cells express ABC
transporters which have been associated with multidrug resistance
by lowering the intracellular accumulation of cytotoxic drugs [9].
Of particular interest is ABCB5 which shares 73% of sequence
homology with ABCB1 (P-gp, MDR1) [10,11]. Firstly detected in
tissues derived from the neuroectodermal lineage including
melanocyte progenitors [10], melanoma cell lines and patient
specimens [11–14], ABCB5 expression was also found in other
tissues [15–17] but is restricted to a subpopulation of cells. In
melanoma, ABCB5-expressing cells are endowed with self-renewal,
differentiation and tumorigenicity abilities [18,19]. Their abun-
dance in clinical melanoma specimens correlates positively with
the neoplasic progression suggesting that ABCB5 expression is
associated with tumor aggressiveness. Moreover, the growth of
melanoma xenografts in mice was delayed when the animals
were treated with a monoclonal anti-ABCB5 antibody [18].
As a member of the ABC transporter family, ABCB5 is thought
to play a role in drug efflux. This was supported by experiments
measuring the intracellular accumulation of Rhodamine 123 [10]
or doxorubicin in melanoma [14] and hepatocarcinoma cells
[15,16]. Nevertheless, the level of resistance of melanoma ABCB5-
expressing cells to relevant chemotherapeutic drugs remains
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junknown. Here, we demonstrated that ABCB5
+ cells display
a survival advantage over ABCB5
2 cells upon anti-melanoma
treatment. We show that: 1) ABCB5-expressing cells selectively
survive over ABCB5
2 cells after a temozolomide treatment
inducing a significant tumor regression in the WM-266-4
xenograft model 2) ABCB5-expressing cells are more abundant
in melanomas from patients treated with dacarbazine 3) in vitro,
dacarbazine but also vemurafenib and other drugs induce an
increase in the ABCB5-expressing cell population at doses that are
cytotoxic for the bulk cells.
Results
ABCB5 Expression is Restricted to a Subpopulation of
Melanoma Cells
To assay the variation of the expression of ABCB5, we first
devised the methodology to detect the presence of ABCB5-
expressing cells in a panel of melanoma cell lines using a rabbit
polyclonal antibody raised against a peptide derived from the
ABCB5 protein sequence (ABCB5-Ab
Rock). In the WM-266-4 cell
line, this antibody consistently labels a subpopulation of living cells
that can be distinguished among the bulk of cells by flow
cytometry (figure 1A). The proportion of positive cells is low but
significant and reproducible within the repeated experiments. The
specificity of the labelling was assessed by depletion experiments
using RNAi interference. The siRNA-mediated down-regulation
of the ABCB5 mRNA expression, as measured by Q-PCR, was
associated with a strong reduction of the ABCB5
+ population to
37% of the control (figure 1B). In addition, we confirmed that
ABCB5-expressing cells detected with the ABCB5-Ab
Rock anti-
body are also labelled by the monoclonal 3C2-1D12 one (ABCB5-
Ab
AbD) described earlier [10,14] (data not shown).
The presence of such an ABCB5
+ subpopulation is not
restricted to the WM-266-4 cell line model and was detected in
most of the tested melanoma cell lines, with a proportion ranging
from 1 to 5% of the total cells (figure 1C). Interestingly, the
amounts of the ABCB5 mRNA quantified by Q-PCR and the
percentages of the ABCB5-expressing cells appear to be correlated
for four of the five tested cell lines (figure 1C and D), with the
exception of G361 cells in which an ABCB5
+ subpopulation was
detected despite a relatively low abundance of mRNA.
Of note, the WM-115 cell line derived from a primary
melanoma tumor expresses six times less ABCB5 mRNA than
the WM-266-4 cell line which originates from a metastasis of the
same patient.
ABCB5-expressing Cells are Enriched in the Residual
Tumors after an Anti-melanoma Treatment in vivo
We investigated the effect of an anti-melanoma chemothera-
peutic treatment on the ABCB5-expressing cell subpopulation
in vivo. This was assayed using WM-266-4 tumor cells sub-
cutaneously xenografted in nude mice. Temozolomide was
selected as the anti-melanoma substance. Mice bearing 14-days
tumors were treated at days 14, 16, 18, 21 with the drug doses
known to induce a significant anti-tumor effect. Tumor growth
was followed over a 21 days period (figure 2A) and tumor
specimens were harvested and analyzed for their content in
ABCB5-expressing cells at days 17 and 22. As shown on figure 2B,
an increase in the ABCB5
+ cells ratio is detected 24 h after the
second injection of temozolomide, concomitantly with an efficient
tumor growth inhibition. This ratio increases again at day 22 after
two more drug administrations when a severe mass reduction is
observed. Immunohistochemical analysis of mice tumors with
a different antibody confirms an increased expression of ABCB5 in
tumors from the treated mice (figure 2C).
ABCB5 Expression is Enhanced after Treatment in Clinical
Samples
We analyzed the expression of ABCB5 in human melanoma
metastatic samples obtained from unmatched patients, before and
after treatment. The figure 3 shows that 7 of the 8 samples from
untreated patients display low-staining intensity (on a level-scale
based on the extent and intensity of the staining on the whole
tumor section). By contrast, 4 of the 7 tumors from treated patients
display a higher level of ABCB5 staining. While this difference is
not statistically significant due to the low number of examined
samples, it nevertheless suggests a higher expression of ABCB5 in
tumors from patients having received treatment.
ABCB5-expressing Cells Enrichment upon Cytotoxic
Treatment is Due to their Selective Survival
We aimed at understanding the origin of the ABCB5-expressing
cells enrichment we observed in vivo. WM-266-4 cells were treated
in vitro with dacarbazine which is structurally related to
temozolomide and is active in vitro. Total and ABCB5
+ cells
numbers were monitored simultaneously after a 72 h treatment,
using a range of cytotoxic drug concentrations. While the number
of the bulk cells decreases with increasing concentrations of drug,
the number of ABCB5
+ cells remains above their basal number in
untreated sample (figure 4A). The survival advantage of ABCB5
+
cells was also found in G-361 and SK-MEL-28 cell lines (figure 4B
and 4C) and was confirmed with a different antibody (data not
shown). In addition to the survival, an increase in ABCB5
+ cell
numbers were detected to a certain extent in the different cell lines
analyzed. This was particularly clear in the WM-266-4 cells in
which ABCB5
+ cells are increased by a two-fold factor (figure 4A).
The dose-response profile is biphasic, with a maximum effect at
a concentration that induces 50–75% of cytotoxicity on the bulk
cells. At higher concentrations, the ABCB5
+ cells numbers
decrease and reach the basal control value (100%). The same
response profiles were obtained when melanoma cells were treated
with vemurafenib (figure 4D–4F). Moreover, the numbers of
ABCB5
+ cells detected upon vemurafenib are significantly higher
than with dacarbazine. By contrast, under doxorubicin exposure,
the numbers of ABCB5
+ cells decrease with increasing concentra-
tions suggesting that they are sensitive to the cytotoxic treatment.
Nevertheless, they display a slight survival advantage over the bulk
cells (figure 4G–4I).
Dacarbazine Treatment Stimulates the Neo-synthesis of
the ABCB5 Protein and its Exposure at the Cell Surface
The results shown above suggest that, in addition to being less
cytotoxic for ABCB5
+ cells than for the bulk cells, dacarbazine
has other effects that participate to increase the ABCB5
+ cells
number detected after treatment. In order to determine a possible
role of protein neo-synthesis and vesicular trafficking, we studied
the effect of cycloheximide and brefeldin A on ABCB5
expression. We measured both the level of ABCB5 at the cell
surface via the fluorescence intensity and the number of cells
expressing a detectable level of ABCB5 via the percentage of
ABCB5
+ cells (figure 5 and figure S1). Cycloheximide does not
affect the basal level of ABCB5 at the surface of untreated cells,
but reverses its increase when cells are treated with either
dacarbazine or doxorubicin (figure 5A). Concomitantly, it
reduces the percentage of ABCB5
+ cells in untreated cells or in
dacarbazine-treated cells. Cycloheximide has no significant
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+ cells after doxorubicin
treatment (figure 5B).
Brefeldin A has no effect on either the basal expression of
ABCB5 or the basal number of detected ABCB5
+ cells in
untreated cells. But it reduces both parameters in dacarbazine-
treated cells suggesting that trafficking participates to increase the
ABCB5 expression at the cell surface. No significant effect was
seen with doxorubicin.
Selective ABCB5-expressing Cells Survival upon
Dacarbazine Occurs with Other Clinically Used Drugs and
is Unrelated to ABCB1 Expression
The ABCB5 protein is barely detectable in untreated WM-266-
4 cells by Western blot analysis (figure 6A). By contrast, treatment
with dacarbazine, vemurafenib or gemcitabine (which also leads to
enrichment of ABCB5-expressing cells) induces an increased signal
corresponding to a protein at the expected molecular weight of
85 kDa. Concordantly with the lack of increase of ABCB5
+ cells
under doxorubicin exposure, no enrichment of the ABCB5 protein
was seen in doxorubicin-treated samples.
We analyzed the effect of different other drugs on ABCB5-
expressing cells. The percentages of ABCB5
+ cells were monitored
by flow cytometry after 72 h-treatments at their respective EC50
(figure 6B). All the tested drugs except doxorubicin increase by
a factor 3 to 9 the percentage of ABCB5
+ cells among the
surviving cells.
Because the expression of different ABC transporters has been
observed in melanoma, we evaluated their potential implication in
the ABCB5
+ cells survival upon dacarbazine as well as other
chemotherapeutic agents. As shown by flow cytometry experiments
(figure 6C), ABCB1 is expressed on a very rare subpopulation in
Figure 1. ABCB5 is expressed on the surface of a subpopulation of melanoma cells. WM-266-4 cells were surface-labelled with the ABCB5-
Ab
Rock antibody and analyzed by flow cytometry. ABCB5
+ cells (right contour plot) were gated on viable cells (DAPI-negative) according to the
isotype control (left contour plot). Inserts (dot plots) display the gating of the positive cells (A). WM-266-4 cells were treated with a siRNA designed to
target ABCB5 (si-ABCB5). After 72 h, the cells were analyzed for their ABCB5 mRNA content and ABCB5 surface expression. The left and right
histograms show respectively the relative expression of ABCB5 mRNA normalized to the ABCB5 mRNA in cells treated with a control siRNA (si-ctrl),
and the percentage of ABCB5
+ cells among total cells (n=3). The corresponding contour plots are shown (B). Different melanoma cell lines were
analyzed for their ABCB5 surface expression (C) or their ABCB5 mRNA content (D) (n=3).
doi:10.1371/journal.pone.0036762.g001
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ABCB1
+ subpopulation is not enriched after a dacarbazine (or
gemcitabine) treatment. Non significant increases in the percent-
ages of ABCB1
+ cells were found after treatment with vindesine,
paclitaxel, camptothecin and etoposide. Q-PCR experiments
confirmed the low level of ABCB1 expression in the WM-266-4
cells compared to the ABCB1
+ cells KB and KB-V1 (figure 6D and
table S1). Some variations were detected in the ABCB1 expression
after drug treatment, but they are not statistically significant.
The expression of ABCC1 and ABCG2 was also measured by
Q-PCR. While these transporters are more abundant than
ABCB1, their expressions remain unchanged after drugs treat-
ments (figure 6D and table S1).
Discussion
Reference chemotherapies used in clinics demonstrated their
impact on acquired resistance of tumor cells. The resistance
phenotype can then be exploited by the tumor cells as a selective
advantage to reconstitute the tumor mass [20]. In the present work
focused on melanoma, we show that ABCB5
+ cells have a survival
advantage over the bulk of tumor cells when they are exposed to
different cytotoxic compounds, including drugs that are used in
melanoma treatment.
ABCB5 expression was initially detected in a subpopulation of
a melanoma cell line (G3361), as well as in melanoma samples
obtained from patients [10,18]. Here, we re-examined ABCB5
cell-surface expression by flow cytometry in five melanoma cell
lines using a different anti-ABCB5 antibody [21]. As previously
shown elsewhere [14,18], we noticed that a subpopulation of cells
was consistently surface-labelled. We confirmed the specificity of
this labelling by ABCB5 silencing experiments and co-labelling
experiments with a different anti-ABCB5 antibody. The propor-
tions of this ABCB5
+ cells subset vary in the different cell lines
but stay in a range that is similar to the frequency reported for
the G3361 cell line [14]. This variability is in agreement with
previous analyses of a panel of melanoma cell lines [13,14,21]
and was confirmed when measuring the ABCB5 mRNA content
by Q-PCR.
When examining the ABCB5 mRNA expressing cell lines, we
found a significantly higher proportion of ABCB5
+ cells in the
WM-266-4 cell line that originates from a metastasis, compared to
the WM-115 cells from the primary tumor of the same patient.
Interestingly, it was previously shown that ABCB5 expression level
Figure 2. ABCB5-expressing cells are enriched in the residual tumors after an anti-melanoma treatment in vivo. WM-266-4 cells (5610
6
cells) were injected subcutaneously in Swiss nude mice. Fourteen days later, mice were treated by repeated i.p. injections of either temozolomide
(80 mg/kg) or vehicle following the schedule indicated by the black arrows. The tumoral volumes were monitored and the means of measured
volumes respectively for temozolomide-treated and vehicle treated tumors are as follows: 180 mm
3 and 175 mm
3 at day 14; 264 mm
3 and 295 mm
3
at day 16; 178 mm
3 and 444 mm
3 at day 18; 84 mm
3 and 699 mm
3 at day 21. (A). 24 h after the injections at days 16 and 21 (d17 and d22), tumors
were recovered, dissociated and the cell suspensions were searched for the presence of human ABCB5
+ cells by flow cytometry (B) (medians are
represented as black lines). Tumors recovered at day 17 were analyzed by immunohistochemistry for their ABCB5 expression (C).
doi:10.1371/journal.pone.0036762.g002
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that the couple WM-115/WM-266-4 tumor cell lines might be an
interesting in vitro model to study the role of the ABCB5 protein
and of ABCB5-expressing cells in melanoma aggressiveness.
The numbers of ABCB5-expressing cells detected by flow
cytometry correlate with the ABCB5 mRNA level except in the G-
361 cell line. In WM-266-4 cells, we showed that inhibitors such as
brefeldin A and cycloheximide affect this number. This suggests
that, in addition to RNA level, expression of ABCB5 at the cell
surface depends also on the rate of the protein synthesis and
trafficking toward the cytoplasmic membrane. We thus can not
exclude that some of these events are particularly enhanced in the
G-361 cell line, leading to the detection of a significant number of
ABCB5-expressing cells despite a low abundance of ABCB5
mRNA as measured on the total cell population.
As a member of the ABC transporters family, ABCB5 was
suggested to participate to the chemoresistant phenotype of
melanoma cells [1,12,14]. A direct role of ABCB5 as a functional
ABC transporter was assayed with doxorubicin, using the
fluorescent properties of this well known ABCB1 substrate
[14,16,21]. Nevertheless the behaviour of the ABCB5
+ sub-
population upon anti-melanoma drugs remains unknown. We
addressed this question taking advantage of the anti-melanoma
effect of temozolomide on subcutaneaous WM-266-4 tumors
grafted in mice. Temozolomide is a pro-drug that, once
metabolized, acts with a similar molecular mechanism and
efficiency than dacarbazine [22]. Its therapeutic potency is well
mimicked in our xenograft model since an objective tumor
regression was measured. Here we show that, in vivo, the regression
of melanoma tumor upon temozolomide treatment is associated
with a selective survival and an increased number of cells that
express ABCB5 protein on their surface.
In order to extend this observation to human patient tumors, we
analyzed the ABCB5 expression in clinical samples. Since ABCB5
expression has been shown to vary according to the melanoma
stage [18], we restricted our study to skin metastases from
untreated patients and from patients who relapsed after a first
chemotherapy episode. Interestingly, the highest levels of ABCB5
expression were found in metastases from treated patients. This
result is consistent with our in vivo findings and provides additional
support to the observation that ABCB5-expressing cells are
enriched upon anti-melanoma treatment.
We investigated this apparent ABCB5
+ cells enrichment in vitro
by monitoring the absolute number of ABCB5-expressing cells.
We focused our analysis on the effects of dacarbazine that was,
until now, the reference treatment for metastatic melanoma [4]
and vemurafenib that recently proved efficiency in melanoma with
BRAF V600E mutation [6]. Using different cell lines that bear the
BRAF V600E mutation, we showed that ABCB5
+ cells survive to
both drugs at doses that are efficient in killing ABCB5
2 cells. The
loss of viability detected at higher doses suggests that the
mechanisms triggered to protect the cells from the cytotoxic stress
are overwhelmed and, consequently, become inefficient. By
contrast, ABCB5
+ cells are more sensitive to the doxorubicin
cytotoxic effect. In vitro cell treatments with dacarbazine were
performed as long as two weeks (not shown). During the first week
of treatment, we observed that the proportion of ABCB5-
expressing cells continues to increase while the total number of
cells decreases. After two weeks of treatment without interruption,
proliferation resumes. Simultaneously, the proportion of ABCB5
+
cells progressively decreases to a percentage that is similar to the
Figure 3. ABCB5 expression is increased in melanoma tumors obtained from treated patients. Skin metastases specimens from
respectively 8 untreated and 7 treated patients were analyzed by immunohistochemistry for their ABCB5 protein expression. The ABCB5 staining
intensity was ranked in four arbitrary classes according to the intensity and the extent of the labelling. Representative staining of two levels of
intensity (left panel: isotypic control) (A). Repartition of the specimens in the different classes (B). The two groups of specimens (untreated versus
treated) have been compared with the non parametric Kruskall Wallis test (p,0.30).
doi:10.1371/journal.pone.0036762.g003
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term surviving of cells and the recurrence of a heterogeneous
population after a chemotherapeutic episode.
Both dacarbazine and doxorubicin stimulate the up-regulation
of ABCB5 at the cell surface through protein neo-synthesis and
trafficking. This might explain the slight difference consistently
found between ABCB5
+ cells and bulk cells cytotoxicity curves
obtained with doxorubicin. But, as previously reported [23], we
did not detect a doxorubicin-induced up-regulation by Western
blot analysis since the frequency of ABCB5
+ cells remains
unchanged and stays very low after the treatment. Interestingly,
dacarbazine has an additional effect leading to the neo-expression
of ABCB5 at the surface of some cells. As previously reported with
other substances [11], it up-regulates the ABCB5 mRNA level, but
interacts also with the protein neo-synthesis. In addition, it induces
the surface expression of ABCB5 on some cells through a process
related to the intracellular vesicular traffic. The mechanisms
underlying this observation remain to be understood.
We extended our analysis to a panel of cytotoxic compounds
and found that drugs from various therapeutic classes induce
a substantial increase in ABCB5
+ cells in the surviving cellular
population. One of the most potent chemoinducer is camptothe-
cin. Interestingly, ABCB5 gene expression was found inversely
correlated to camptothecin activity among cell lines of the NCI
panel [14]. Furthermore, depletion using a siRNA that targets
a short variant of ABCB5 was shown to sensitize melanoma cells to
the camptothecin cytotoxic effect [12].
The peculiar cytotoxicity of doxorubicin on ABCB5-expressing
cells remains to be understood. It suggests that the efficiency of
ABCB5 as a transporter might be higher for drugs such as
dacarbazine, vemurafenib, camptothecin, gemcitabine than for
doxorubicin. To date, no transfection data are available to
establish which substrates are preferentially transported by
ABCB5. In addition, the length of the protein detected so far
(isoform 2) raises unsolved questions about the three-dimensional
structure of ABCB5 and its functionality as a transporter.
The implication of other ABC transporters in the melanoma
resistance to chemotherapeutic drugs was extensively studied [24–
28] and remains controversial. We wondered if various transpor-
ters might be associated with the selective survival of ABCB5
+
cells. This hypothesis was assayed assuming that, if other ABC
transporters were co-expressed by ABCB5
+ cells, we should expect
their concomitant enrichment with ABCB5 after drug treatment.
Our data show here that the survival of ABCB5
+ cells upon
dacarbazine is not associated with ABCB1, ABCC1 or ABCG2
expression. An implication of ABCB1 in the response to drugs
known as ABCB1 substrates can not be completely excluded, but
does not appear predominant in the survival of ABCB5
+ cells. A
recent report suggests that a new member of the ABC family,
ABCB8, is associated with doxorubicin resistance [29]. A similar
expression level of such a transporter in ABCB5
+ and ABCB5
2
cells might explain the lack of differential sensitivity of these cells to
doxorubicin but this was not investigated in our study.
Different studies suggest that, in addition to a plasma membrane
insertion, some ABC transporters may also be located on
subcellular compartments where they play a role in trapping
drugs in the cytoplasm before export [30,31]. The preferential
ABCB5 expression in melanocytes and melanomas [11] pointed to
a potential link between ABCB5 and the melanosomal compart-
ment in which melanin is synthetized and stored. A role of
melanosomes was proposed for melanoma cells chemoresistance to
cisplatin [8,32]. Nevertheless, the WM-266-4 cells lack a functional
melanosomal compartment [33], suggesting that the survival of
ABCB5
+ during dacarbazine treatment is not associated with
melanosomes. Moreover, ABCB5
+ cells were also found in
amelanic tissues [15,16]. Thus the potential link of ABCB5 with
this cellular detoxification pathway remains unclear.
Taken together, our results suggest that anti-melanoma
chemotherapy participates to the chemoresistance acquisition that
leads to clinical relapse, by selecting tumor cell subpopulations
such as ABCB5-expressing cells. This is of particular importance
in the chemoresistance occuring upon dacarbazine treatment, but
is reinforced in the context of the clinical use of vemurafenib
whose strong therapeutic interest is strongly hampered by rapid
relapses observed after a few months [7].
ABCB5 appears as a dual potential therapeutic target [34]. On
the one hand, the functions of the protein per se may confer tumor
cells a survival advantage through the tumor progression and
potentially the chemotherapeutic treatment. This last point was
recently addressed in colorectal cancer in which ABCB5 was
shown to identify a therapy-refractory tumor cell population [16].
On the other hand, the protein ABCB5 might not mechanistically
participate to this selective survival, but represents a marker for
a subcellular population endowed with intrinsic stem cell-like
properties [18]. While the stemness of these cells remains
controversial [35], their peculiar properties in terms of tumorige-
nicity [18], resistance and more recently, immunosuppression [36]
remain to be further explored and monitoring the ABCB5
+ cells
might be an important parameter to evaluate the long term
efficiency of melanoma treatment.
Materials and Methods
Cell Culture
The WM-266-4, WM-115, G-361, A-375 and SK-MEL-28
cell lines were obtained from the American Type Culture
Collection and the KB and KB-V1 cell lines from the Deutsche
Sammlung von Mikrooganismen und Zellkulturen. The WM-
266-4, WM-115, G-361, A-375 and KB cells were grown in
DMEM (Invitrogen, Cergy Pontoise, France) supplemented with
10% fetal bovine serum (Sigma, Lyon, France), 2 mM glutamine,
100 UI/mL penicillin-streptomycin and 1.25 mg/mL fungizone
(both from Invitrogen) in 5% CO2 atmosphere. The SK-MEL-28
cells were grown in MEM (Invitrogen) supplemented with 10%
fetal bovine serum, 2 mM glutamine, 100 U/mL penicillin-
streptomycin, 1.25 mg/mL fungizone, 1 mM sodium pyruvate
and 0.1 mM non essential amino acids (all from Invitrogen) in
5% CO2 atmosphere. The KB-V1 cells were grown in MEM
(Invitrogen) supplemented with 15% fetal bovine serum, 2 mM
glutamine, 100 U/mL penicillin-streptomycin, 1.25 mg/mL fun-
gizone, 1 mM sodium pyruvate and 0.1 mM non essential amino
acids (all from Invitrogen) and 200 ng/mL vinblastine in 5%
Figure 4. ABCB5-expressing cells survive upon dacarbazine treatment. WM-266-4 (A,D,G), G-361 (B,E,H) and SK-MEL-28 cells (C,F,I) were
treated at the indicated concentrations of dacarbazine (A–C), vemurafenib (D–F) and doxorubicin (G–I). After 72 h, the total viable cells were
numbered using an automated cell viability analyzer. The percentages of viable ABCB5-expressing cells (among viable cells gated on DAPI-negative
cells) were analyzed by flow cytometry. The numbers of total cells (white symbols) are reported as percentages of the number of cells in the
untreated control sample. The numbers of viable ABCB5
+ cells (black symbols) were calculated from the total cell numbers and ABCB5
+ cells ratio, and
reported as percentages of the viable ABCB5
+ cells number in the control sample. ABCB5
+ cells represent respectively 3%, 3.5% and 5% of the total
cells in the WM-266-4, G-361 and SK-MEL-28 cell lines.
doi:10.1371/journal.pone.0036762.g004
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using an Automated Cell Viability Analyzer (Beckman Coulter
Vi-Cell).
Flow Cytometry Analysis
The surface expression of ABCB5 and ABCB1 was analyzed
respectively with a rabbit polyclonal anti-ABCB5 antibody
ABCB5-Ab
Rock (Rockland, Gilbertsville, PA, USA) or a mouse
Figure 5. Enrichment in ABCB5-expressing cells is associated with protein neo-synthesis and ABCB5 relocation at the cell-surface.
WM-266-4 cells were treated with dacarbazine, doxorubicin or vehicle (NT) for 72 h. Cycloheximide (A–B) or brefeldin A (C–D) were added
respectively 24 h and 4 h before the treatment end-point. Cells were labelled for ABCB5 and analyzed by flow cytometry. The means of fluorescence
intensity of the ABCB5
+ cells from three independent experiments were reported in A and C. Fluorescence intensity histograms of representative
experiments are shown in the figure S1. The number of ABCB5
+ cells was reported in B and D as a percentage of the ABCB5
+ cell number in the
vehicle-treated sample.
doi:10.1371/journal.pone.0036762.g005
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AbD (clone 3C2-1D12, AbD
Serotech, Oxford, UK) and a monoclonal anti-ABCB1 antibody
(clone MM4.17, Millipore, Molsheim, France). Cells were de-
tached with 2 mM EDTA in PBS and incubated for 45 min at
4uC with 6 mg/mL of ABCB5-Ab
Rock antibody, 10 mg/mL of
ABCB5-Ab
AbD antibody, 5 mg/mL anti-ABCB1 or corresponding
isotype antibodies (Invitrogen). The cells were washed, counter-
stained with Alexa-488-conjugated goat anti-rabbit or Alexa-647-
conjugated goat anti-mouse Ig antibodies (Invitrogen) and finally
incubated with 0.5 mg/mL DAPI (Sigma). The cells were
analyzed with a LSRII flow cytometer using the Diva software
(both from BD Biosciences, Le Pont-De-Claix, France). ABCB5
and ABCB1 expression were monitored on live cells (gated as
DAPI-negative cells).
Figure 6. Quantification of ABCB5- and ABCB1-expressing cells after cytotoxic treatments. WM-266-4 cells were treated for 72 h with the
indicated concentrations of doxorubicin, dacarbazine, vemurafenib, gemcitabine or with vehicle (NT) and ABCB5 expression was analyzed by Western
blot. Band intensities were quantified and variations are indicated as fold increases in treated versus untreated samples (A). WM-266-4 cells were
treated with various drugs at their EC50 for 72 h. The percentages of positive cells among surviving cells were measured by cell surface labelling and
flow cytometry analysis for ABCB5 (B) or ABCB1 (C). The relative mRNA expression of ABCB5, ABCB1, ABCC1, ABCG2 and HMBS as the house-keeping
gene was measured by Q-PCR (see also table S1) and the amplified products were run on agarose gel after 29 cycles except for ABCB1 (32 cycles) (D).
doi:10.1371/journal.pone.0036762.g006
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ABCB5 expression was silenced by transfection of siRNA with
lipofectamine 2000 Reagent (Invitrogen) after 24 h of serum
deprivation. ABCB5 siRNA and the control luciferase siRNA were
from Applied Biosystem. The targeted ABCB5 sequence was 59-
ggucggacuacaaucgugg-39. Cells were analyzed for ABCB5 expres-
sion 72 h after the transfection.
Quantitative Real-Time PCR
RNA was prepared using the RNeasy Mini Kit (Qiagen,
Courtaboeuf, France) and quantified by the NanoDrop technology
(ThermoScientific). Total RNA (1 mg) was reverse transcribed into
cDNA with the iScript cDNA Synthesis Kit (Bio-Rad). PCR were
performed on an iCycler (Bio-Rad, Marne-la-Coquette, France)
using the iQ SYBR Green Supermix (Bio-Rad) kit. All PCR
included amplification of HMBS (hydroxymethylbilane synthase)
and RPLP0 (ribosomal protein, large, P0) as normalizing controls.
The primer sequences were designed as follows: ABCB5 Forward
59-ccaaatcgggggctgcgcatctgtt-39 and Reverse 59-agccgctgctcccca-
caaatgcta-39 for ABCB5 isoform 1 and 2; ABCB1 Forward 59-
tgacatttattcaaagttaaaagca-39 and Reverse 59- tagacactttatgcaaa-
catttcaa-39; ABCC1 Forward 59- agtggaacccctctctgtttaag-39 and
Reverse 59- aacagcagcacggtgtagaa-39; ABCG2 Forward 59-
ccgcgacagtttccaatgacct-39 and Reverse 59- gccgaagagctgctga-
gaactgta-39; HMBS Forward 59-atacagacggacagtgtggtgg-39 and
Reverse 59-ccctgtggtggacatagcaatga-39; RPLPO Forward 59-
ggcgacctggaagtccaact-39 and Reverse 59-ccatcagcaccacagccttc-39.
For each gene, the relative expression ratio was calculated by the
DDCt method.
In vivo Study
Animals were handled and cared for in accordance with the
Guide for the Care and Use of Laboratory Animals (National
Research Council, 1996) and the European Directive EEC/86/
609, under the supervision of authorized investigators. All
experiments performed were controlled and approved by the
institutional Animal Ethical Committee and by the ‘‘Comite ´
Re ´gional d’Ethique pour l’Expe ´rimentation Animale’’ (Midi
Pyre ´ne ´es, France) (protocol approval number MP/05/16/04/06).
WM-266-4 cells (5610
6) were implanted subcutaneously into
homozygous female athymic nude mice (Ico:Swiss-nu/nu, Charles
River, Saint-Germain-sur-L’Arbresle, France) and allowed to
increase to a median value of 100–200 mm
3. After randomisation
in treatment cages, temozolomide (Molekula, Dorset, UK) was
administered i.p. as 4 intermittent injections over 8 days according
to a [q2d63] schedule at 80 mg/kg. In each chemotherapy trial,
mice were checked daily, with any adverse clinical reactions noted
and deaths recorded. Mice were weighed three times a week
during the treatments. Tumors were measured by callipers three
times weekly and tumor volumes (mm
3) were estimated as=0.5
(length6width6thickness). Results are presented for experiments
involving 3–6 mice per experimental group. T/T0 (%)=mean of
(tumor volume on day X of treatment/tumor volume on day 0 of
treatment)6100.
The tumors were harvested and dissociated with collagenase
(1000 UI/mL, Sigma), elastase (30 UI/mL, Sigma) and DNAse
(1 mg/mL, Sigma) in culture medium. After filtration on 70 mm
sieves, the cellular suspensions were labelled for cell surface
ABCB5 then CD44 using an anti-human CD44 antibody
conjugated to Alexa-647 (clone C26, Beckton Dickinson Pharmin-
gen, San Diego, CA, USA) in order to distinguish tumor cells from
the infiltrating host cells. ABCB5 labelling was analyzed on live
cells (gated as DAPI-negative cells) expressing CD44. In addition,
tumor samples from day 17 were paraffin-embedded for immu-
nohistochemistry analyses.
Clinical Cancer Specimens
A total of 15, formalin-fixed paraffin-embedded (FFPE)
melanoma tumor samples from 8 patients were obtained after
informed consent from the tumor bank of the Department of
Pathology, Toulouse-Purpan University Hospital (France). Path-
ological specimens were collected between 2009 and 2011 and
consisted of skin metastases. Tumor samples were collected before
(n=7) and after (n=8) treatment of the melanoma with
monochemotherapy (dacarbazine or fotemustine). All patients
presented melanoma metastases at the time the tumor sample was
taken (AJCC stage IV). In 3 patients, molecular analysis of the
tumor revealed the presence of a BRAF V600E mutation, the
mutation was absent in 2 patients. Due to technical artifact, the
mutation was not evaluated in 3 patients. In 3 patients, a stable
disease was observed after 1 cycle of monochemotherapy
(dacarbazine).
Immunohistochemistry
For immunohistochemistry, 4-mm sections were deparaffinized
and rehydrated. Endogenous peroxide activity was inhibited with
a 15 min incubation in 3% (v/v) hydrogen peroxide. An
automated staining module (Dako, Glostrup, Denmark) was then
used to conduct histological staining. Slides were incubated with
a rabbit polyclonal anti-ABCB5 antibody ABCB5-Ab
Sigma (Sigma)
followed by a secondary Horse Radish Peroxidase-rabbit antibody
and visualized using a colorimetric method (Envision kit, Dako,
Glostrup, Denmark). All of the colorimetric immunohistostained
sections were analyzed using a Nikon (Eclipse E800) microscope.
Semiquantitative double-blind evaluation was conducted by
scoring the estimated staining intensity of the ABCB5-labelling.
Cell Treatments with Chemotherapeutic Drugs
The WM-266-4 cells were seeded at 10
5 cells per well in 24-well
culture plates and treated after a 24 h period to allow cell
attachment. The cells were harvested for analysis 72 h after the
treatment onset and were counted using an Automated Cell
Viability Analyzer (Beckman Coulter Vi-Cell) before flow
cytometry experiments.
The half maximal effective concentration (EC50) of each drug
was determined using a cytotoxicity assay (ATP-lite assay, Perkin
Elmer, Courtaboeuf, France). The EC50 on WM-266-4 cells are:
3610
28 M for vinblastine (Sigma), 3610
29 M for vindesine (Lilly,
Suresnes, France), 3610
29 M for vincristine (Sigma), 3610
28 M
for paclitaxel (Sigma), 1610
25 M for dacarbazine (Sigma),
5610
28 M for doxorubicin (Sigma), 1610
26 M for etoposide
(Sicor, Irvin, CA, USA), 2610
28 M for gemcitabine (Lilly),
2610
28 M for camptothecin (Acros, Thermo-Fisher, Illkirch,
France) and 4610
27 M for vemurafenib (Euromedex, Selleck-
chem).
When mentioned, cycloheximide (10 mg/mL, Sigma) or
brefeldin A (10 mg/mL, Sigma) were added respectively 24 h
and 4 h before the end-points of the cytotoxic treatments.
Western Blot Analysis
Cells were lysed with a Dounce homogenizer at a concentration
of 10
7 cells/mL in the lysis buffer (20 mM Tris-HCl, 150 mM
NaCl, 5 mM MgCl2, 5 mM EGTA, 5 mM NaF, 1 mM NaVO4,
0.1% Nonidet-P40 and 0.1% Triton X114 complemented ex-
temporaneously with 1 mM DTT and protease inhibitors cocktail
(Calbiochem, Merck Chemical, Nottingham, UK). The unbroken
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and washed once with 100 mL of lysis buffer. The post-nuclear
supernatant was centrifuged at 72000 g for 30 min. The
membrane pellet was solubilised in 2% SDS, 15% glycerol,
50 mM dithiothreitol in 10 mM Tris pH 8, heated at 37uC for 1 h
and sonicated. Samples were run on 8% SDS-PAGE and
transferred onto polyvinylidene difluoruride membranes. After
saturation with 5% dry milk in TBS-0.1%Tween 20, membranes
were incubated with either anti-ABCB5 antibody (1/2000 diluted
in TBS-0.1%Tween 20-1% BSA) or anti-actin antibody (clone C4,
Millipore, 1/1000 in 5% dry milk). After wash, the membranes
were revealed with peroxydase-linked secondary goat anti-mouse
or rabbit antibody (Jackson ImmunoResearch, Suffolk, UK) and
the signals were detected by ECL (GE Healthcare). Band
quantification was performed with the Quantity One 1-D Analysis
Software (Bio-Rad Laboratories, Inc.) and normalized using actin
band intensities.
Statistical Analysis
Data reported are expressed as means 6 s.d. of at least three
independent experiments. Statistical significance was measured
using the Mann and Whitney sum rank test from SigmaStat3.1
software, where p,0.05 was considered to be statistically
significant (marked with *) and p,0.01 and p,0.001 was
considered highly statistically significant (marked respectively with
** and ***).
Supporting Information
Figure S1 Enrichment in ABCB5-expressing cells is
associated with protein neo-synthesis and ABCB5 re-
location at the cell-surface. WM-266-4 cells were treated with
doxorubicin or dacarbazine for 72 h. Cells were either untreated
(A) or treated with brefeldin A (B) 4 h before the treatment end-
point. A similar experiment was performed except that cells were
either untreated (C) or treated with cycloheximide (D) 24 h before
the treatment end-point. Cells were labelled for ABCB5 and
analyzed by flow cytometry. Histograms show the fluorescence
intensity of the ABCB5 cells in representative experiments. The
corresponding mean of fluorescence intensity is indicated in each
histogram.
(TIF)
Table S1 Quantification of ABCB5, ABCB1, ABCC1 and
ABCG2 mRNA expression after cytotoxic treatments.
WM-266-4 cells were treated with various drugs at their EC50 for
72 h. The relative mRNA expression of ABCB5, ABCB1,
ABCC1, ABCG2 and HMBS as the house-keeping gene was
measured by Q-PCR and the Ct values are reported.
(TIF)
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